Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23072001 | 0.79 | CYP1A2 (0.44) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL11181015 | 0.78 | SCD (0.42) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL31556854 | 0.72 | CYP1A2 (0.36) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL21623957 | 0.72 | CYP1A2 (0.36) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL31556858 | 0.72 | CYP1A2 (0.36) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL21623955 | 0.72 | CYP1A2 (0.36) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL21623939 | 0.71 | CYP1A2 (0.38) | CYP1A2KMT2ABPTFALDH1A1CHRNB2 | |
| SCHEMBL15542949 | 0.71 | CYP1A2 (0.38) | CYP1A2KMT2ABPTFALDH1A1CHRNB2 | |
| SCHEMBL15011617 | 0.71 | SCD (0.42) | CYP1A2KMT2ABPTFSMN1; SMN2ALDH1A1 | |
| SCHEMBL31556859 | 0.71 | CYP1A2 (0.38) | CYP1A2KMT2ABPTFALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | GABRA5, GABRB1, GABRA1 | CYP1A2 164/4885KMT2A 3263/4885BPTF 2265/4885 |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | GABRA5, GABRB1, GABRA1 | CYP1A2 157/4885KMT2A 3247/4885BPTF 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.